NLS Pharmaceutics AG
NLSPW0.018USD
0.000
Close 12/24, 13:00（ET）Quotes delayed by 15 min
0.00Market Cap
--P/E TTM
More Details of NLS Pharmaceutics AG Company
NLS Pharmaceutics AG, formerly NLS 1 Pharma AG, is a Switzerland-based company that operates as a biopharmaceutical company. The Company focuses on development of medicines for neurobehavioral and neurocognitive disorders treatment. The Company serves customers worldwide.
NLS Pharmaceutics AG Info
Ticker SymbolNLSPW
Company nameNLS Pharmaceutics AG
IPO dateJan 29, 2021
CEOMr. Alexander Zwyer
Number of employees- -
Security typeCompany Warrant
Fiscal year-end- -
AddressThe Circle 6
CityZUERICH
Stock exchangeNASDAQ Capital Market Consolidated
CountrySwitzerland
Postal code8058
Phone41445122150
Websitehttps://nlspharma.com/
Ticker SymbolNLSPW
IPO dateJan 29, 2021
CEOMr. Alexander Zwyer
Company Executives of NLS Pharmaceutics AG
Name
Name/Position
Position
Shareholding
Change
Ms. Nicole Fernandez-mcgovern
Ms. Nicole Fernandez-mcgovern
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Independent Director
Independent Director
--
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
--
--
Mr. Alexander Zwyer
Mr. Alexander Zwyer
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Dr. Eric Konofal, M.D., Ph.D.
Dr. Eric Konofal, M.D., Ph.D.
Chief Scientific Officer
Chief Scientific Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Ms. Nicole Fernandez-mcgovern
Ms. Nicole Fernandez-mcgovern
Chief Financial Officer
Chief Financial Officer
--
--
Mr. Olivier Samuel
Mr. Olivier Samuel
Independent Director
Independent Director
--
--
Mr. Gian-Marco Rinaldi
Mr. Gian-Marco Rinaldi
Independent Director
Independent Director
--
--
Ms. Cindy Rizzo
Ms. Cindy Rizzo
Investor Relations
Investor Relations
--
--
Mr. Ronald Hafner
Mr. Ronald Hafner
Independent Chairman of the Board
Independent Chairman of the Board
--
--
Ms. Florence Allouche Aknin
Ms. Florence Allouche Aknin
Independent Director
Independent Director
--
--
Revenue Breakdown
Relevant data have not been disclosed by the company yet.
Relevant data have not been disclosed by the company yet.
By Business
By Region
Relevant data have not been disclosed by the company yet.
Shareholding Stats
Updated: Mon, Nov 17
Updated: Mon, Nov 17
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholders
Shareholders
Proportion
Other
100.00%
Shareholder Types
Shareholders
Proportion
Other
100.00%
Institutional Shareholding
Updated: Sun, Oct 5
Updated: Sun, Oct 5
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
8
86.59K
0.00%
-524.31K
2025Q2
9
258.62K
0.00%
-535.48K
2025Q1
9
258.62K
0.00%
-535.48K
2024Q4
9
575.86K
0.00%
+75.79K
2024Q3
10
481.82K
0.00%
-1.36M
2024Q2
12
1.16M
0.00%
-830.95K
2024Q1
11
1.15M
0.00%
-822.65K
2023Q4
10
1.13M
0.00%
-839.40K
2023Q3
10
1.13M
0.00%
-844.05K
2023Q2
10
1.13M
0.00%
-844.05K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Wolverine Asset Management, LLC
--
0%
-245.00K
-100.00%
Mar 31, 2025
Hudson Bay Capital Management LP
--
0%
-71.36K
-100.00%
Mar 31, 2025
Clear Street LLC
57.76K
0%
+120.00
+0.21%
Jun 30, 2025
Citadel Advisors LLC
--
0%
-18.38K
-100.00%
Jun 30, 2025
Armistice Capital LLC
12.50K
0%
--
--
Jun 30, 2025
Altium Capital Management LP
--
0%
-200.00K
-100.00%
Dec 31, 2024
Susquehanna International Group, LLP
16.33K
0%
+16.33K
--
Jun 30, 2025
UBS Financial Services, Inc.
--
0%
-6.02K
-100.00%
Jun 30, 2024
View more
Related ETFs
Name
Proportion
No Data
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
FAQs
Who are the top five shareholders of NLS Pharmaceutics AG?
The top five shareholders of NLS Pharmaceutics AG are:
Wolverine Asset Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Hudson Bay Capital Management LP holds 0.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 57.76K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 12.50K shares, accounting for 0.00% of the total shares.
Wolverine Asset Management, LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Hudson Bay Capital Management LP holds 0.00 shares, accounting for 0.00% of the total shares.
Clear Street LLC holds 57.76K shares, accounting for 0.00% of the total shares.
Citadel Advisors LLC holds 0.00 shares, accounting for 0.00% of the total shares.
Armistice Capital LLC holds 12.50K shares, accounting for 0.00% of the total shares.
What are the top three shareholder types of NLS Pharmaceutics AG?
The top three shareholder types of NLS Pharmaceutics AG are:
Other
Other
How many institutions hold shares of NLS Pharmaceutics AG (NLSPW)?
As of 2025Q3, 8 institutions hold shares of NLS Pharmaceutics AG, with a combined market value of approximately 86.59K, accounting for --% of the total shares. Compared to 2025Q2, institutional shareholding has increased by --.
What is the biggest source of revenue for NLS Pharmaceutics AG?
In --, the -- business generated the highest revenue for NLS Pharmaceutics AG, amounting to -- and accounting for --% of total revenue.
